2011;254:267?9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for sophisticated prostate cancer. N Engl J Med. 2004;351:1502?2. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing right after docetaxel remedy: a randomised open-label trial. Lancet. 2010;376:1147?4. Quach JM, Askmyr M, Jovic T, et al. Myelosuppressive therapies considerably enhance pro-inflammatory cytokines and straight trigger bone loss. J Bone Miner Res. 2014; doi: ten.1002/jbmr.2415. This study found that myelosuppresive chemotherapies directly result in bone loss. Shandala T, Shen NY, Hopwood B, et al. The part of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J Cell Physiol. 2012;227:2889?7. Georgiou KR, King TJ, Scherer MA, et al. Attenuated Wnt/betacatenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats. Bone. 2012;50:1223?three. Tipples K, Robinson A. Optimal management of cancer treatmentinduced bone loss: considerations for elderly individuals. Drugs Aging. 2011;28:867?three. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73?1. Williams HJ, Davies AM. The effect of X-rays on bone: a pictorial critique. Eur Radiol. 2006;16:619?3. Matsumura S, Jikko A, Hiranuma H, et al. Impact of X-ray irradiation on proliferation and differentiation of osteoblast. Calcif Tissue Int. 1996;59:307?. Szymczyk KH, Shapiro IM, Adams CS. Ionizing radiation sensitizes bone cells to apoptosis. Bone. 2004;34:148?6. Chandra A, Lin T, Tribble MB, et al. PTH1-34 alleviates radiotherapy-induced neighborhood bone loss by improving osteoblast and osteocyte survival. Bone. 2014;67:33?0. Supplies a summary of studies inside the introduction relating to radiotherapy-induced adjustments in osteoclast quantity and activity. Indicates that PTH1-34 may well alleviate radiotherapy-induced bone loss by improving osteoblast and osteocyte survival. Manas A, Casas F, Ciria JP, et al. Randomised study of single dose (8 Gy vs. six Gy) of analgesic radiotherapy plus zoledronic acid in sufferers with bone metastases. Clin Transl Oncol. 2008;ten:281?. Willey JS, Livingston EW, Robbins ME, et al. Risedronate prevents early radiation-induced osteoporosis in mice at various skeletal places. Bone. 2010;46:101?1. Keenawinna L, Oest ME, Mann j.addbeh.2012.10.012 KA, et al. Zoledronic acid prevents loss of trabecular bone just after focal irradiation in mice. Radiat Res. 2013;180:89?9. Longo J, Lutz S, Johnstone C. Samarium-153-ethylene diamine tetramethylene SC144 cancer phosphonate, a beta-emitting bone-targeted radiopharmaceutical, valuable for individuals with osteoblastic bone metastases. Cancer Manag Res. 2013;five:235?2. Roque IF, Martinez-Zapata MJ, Scott-Brown M, et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2011; CD003347. Wissing MD, van Leeuwen FW, van der Pluijm G, et al. Radium223 chloride: extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res. 2013;19:5822?. Summary of radium-223 in prostate cancer individuals, as well as the limitations of at present reported clinical studies with this novel therapy. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival cdev.12038 in metastatic prostate cancer.